Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data
Newly diagnosed lung cancer patients are half as likely to die of the disease if they take Keytruda drug alongside standard chemotherapy, according to data released Monday.
Newly diagnosed lung cancer patients are half as likely to die of the disease if they take a Merck drug alongside standard chemotherapy, according to new trial data that eclipsed doctors’ expectations.
The trial, which compared a combination of chemo and Merck’s blockbuster against chemo alone, found that patients in the combo group were 51 percent more likely to be alive after one year. Those getting
